The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
Epidemiological Parkinson's Risk Modifiers, 2019Study in French Population to Identify Therapies with Repurposing Potential for Parkinson’s Disease
Study Rationale:
There is an urgent need to identify effective, safe and inexpensive drugs for Parkinson’s disease, and over past years, there has been increasing interest on ways to repurpose... -
Improved Biomarkers and Clinical Outcome Measures, 2019Correlating MRI, Pathology and Cognitive Assessments toward Biomarkers of Cognitive Decline
Study Rationale:
Parkinson’s studies are working to identify magnetic resonance imaging (MRI) biomarkers for early diagnosis, disease severity and progression. However, attempts to explore how brain... -
Improved Biomarkers and Clinical Outcome Measures, 2019International Validation of Two Non-motor Symptom Scales in Parkinson’s Disease
Study Rationale:
Non-motor Parkinson’s symptoms can fluctuate with dopaminergic medication effectiveness. Anxiety, sadness, lack of energy and fatigue are common symptoms during the off-medication... -
GBA Biology and Therapies, 2018Structural Characterization of the GCase/LIMP-2 Complex
Study Rationale:
Mutations in the GBA gene are a risk factor for Parkinson’s disease (PD) and cause deficits in the protein GCase. GCase reaches its final destination in the cell, the lysosome, via its... -
Research Grant, 2018Safety and Tolerability of GRF6021 Infusions in People with Parkinson's Disease and Cognitive Impairment
Study Rationale & Design:
Components of blood have been found to improve health and enhance multiple biological functions, including brain function, in older animals. Blood plasma has been... -
Alpha-Synuclein Biology and Therapies, 2019Development of a Novel Intracellular Alpha-synuclein-lowering Strategy based on CRISPR Interference Technology
Study Rationale:
Alpha-synuclein protein accumulates in the brain in Parkinson’s disease. Reducing the impact of this protein in the brain may prevent the degeneration of nerve cells and stop the...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.